About: Clinical benefits of Tocilizumab in COVID‐19‐related cytokine release syndrome in a patient with end‐stage kidney disease on haemodialysis in Australia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical benefits of Tocilizumab in COVID‐19‐related cytokine release syndrome in a patient with end‐stage kidney disease on haemodialysis in Australia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical benefits of Tocilizumab in COVID‐19‐related cytokine release syndrome in a patient with end‐stage kidney disease on haemodialysis in Australia
Creator	Chrysostomou, Anastasia Park, Yeung-Ae Stephen, Shiny
Source	Medline; PMC
abstract	COVID‐19 remains a global pandemic with more than ten million cases and half a million deaths worldwide. The disease manifestations in patients with chronic kidney disease and especially those on haemodialysis are still being understood, with only a few overseas case series, and small observational trials thus far. It appears the disease is more severe in this patient cohort. (1) (1) (1 1) Part of the pathophysiology of severe COVID‐19 is related to accompanying cytokine release syndrome. Tocilizumab, an interleukin‐6 inhibitor, has been trialled for treatment of cytokine release syndrome in COVID‐19, but not yet approved. We present a case of an Australian patient on long‐term haemodialysis with severe COVID‐19 who was successfully treated with Tocilizumab. The peak of her illness was on day 7, with a C‐reactive protein of 624 mg/L (reference <5 mg/L), ferritin of 5293 ng/mL (reference 30‐500 ng/mL), and interleukin‐6 level 1959.7 pg/mL, consistent with cytokine release syndrome. She was severely hypoxic on a ventilator, with rising inotropic requirements. With the use of Tocilizumab there was a significant and immediate response in her inflammatory markers, and she made a steady recovery. The patient was discharged home six weeks after presentation.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1111/nep.13767
bibo:pmid	32776624
has license	no-cc
sha1sum (hex)	d7e643657358e24b4e245d13023cbee4ef4853e7
schema:url	https://doi.org/10.1111/nep.13767
resource representing a document's title	Clinical benefits of Tocilizumab in COVID‐19‐related cytokine release syndrome in a patient with end‐stage kidney disease on haemodialysis in Australia
has PubMed Central identifier	PMC7436382
has PubMed identifier	32776624
schema:publication	Nephrology (Carlton)
resource representing a document's body	covid:d7e643657358e24b4e245d13023cbee4ef4853e7#body_text
is schema:about of	named entity 'ventilator' named entity 'discharged' named entity 'inhibitor' named entity 'reference' named entity 'cytokine release syndrome' named entity 'peak' named entity 'Tocilizumab' named entity 'CHRONIC KIDNEY DISEASE' named entity 'SEVERELY' named entity 'CASES' named entity 'HYPOXIC' named entity 'WORLDWIDE' named entity 'STEADY' named entity 'USE OF' named entity 'INTERLEUKIN-6 ' named entity 'INOTROPIC' named entity 'TEN MILLION' named entity 'WEEKS' named entity 'patient' named entity 'Tocilizumab' named entity 'remains' named entity 'C-reactive protein' named entity 'consistent' named entity 'COVID' named entity 'long-term' named entity 'ferritin' named entity 'cytokine release syndrome' named entity 'COVID' named entity 'COVID-19' named entity 'global pandemic' named entity 'hypoxic' named entity 'Tocilizumab' named entity 'case series' named entity 'COVID' named entity 'Tocilizumab' named entity 'interleukin' named entity 'oxygen saturations' named entity 'CKD' named entity 'critically ill' named entity 'fluid overload' named entity 'Italy' named entity 'COVID' named entity 'COVID-19' named entity 'thrombosis' named entity 'FiO2' named entity 'CRP' named entity 'Tocilizumab' named entity 'nasal prongs' named entity 'Piperacillin-Tazobactam' named entity 'ventilatory support' named entity 'fistula' named entity 'CRS' named entity 'radiographs' named entity 'CRP' named entity 'extracorporeal' named entity 'ICU' named entity 'arteriovenous fistula' named entity 'IL-6' named entity 'confounder' named entity 'fluid balance' named entity 'antibody' named entity 'broad-spectrum antibiotics' named entity 'COVID-19' named entity 'CRS' named entity 'Haematology' named entity 'erythropoietin' named entity 'COVID' named entity 'blood samples' named entity 'CRS' named entity 'inflammatory state' named entity 'SARS' named entity 'community-acquired pneumonia' named entity 'nitric oxide' named entity 'upper respiratory tract' named entity 'IL-6' named entity 'comorbidities' named entity 'ferritin' named entity 'Ceftriaxone' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software